Sinovac Biotech Ltd.
No.39 Shangdi Xi Rd
Haidian District
Beijing
100085
China
Tel: 86-10-82890088
Fax: 86-10-62966910
Website: http://www.sinovac.com/
Email: sinovac@sinovac.com
422 articles about Sinovac Biotech Ltd.
-
SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F
4/29/2022
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2021.
-
It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.
-
There are very few ongoing clinical trials on treatments for Long COVID and there has been what appears to be a successful treatment using Pfizer’s Paxlovid. Read on for more details.
-
Sinovac Amends Shareholder Rights Plan - Feb 22, 2022
2/22/2022
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that its board of directors has amended its shareholder rights plan.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
SINOVAC Reports Unaudited First Half of 2021 Financial Results
12/30/2021
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced its unaudited financial results for the six months ended June 30, 2021.
-
Although it’s not yet clear how dangerous the Omicron variant of COVID-19 actually is, it clearly is very infectious and rates are rising in the U.S. and around the world.
-
The Pfizer-BioNTech vaccine (now Comirnaty®) was fully approved by the U.S. Food and Drug Administration (FDA) on August 23 and boosters of this shot are now available to the most vulnerable Americans.
-
Researchers in China are busy developing several treatments, combining vaccines and drugs for COVID-19, and also working on monoclonal antibodies treatment.
-
SINOVAC Beijing Settled Litigation of Its Business License and Seals
12/3/2021
SINOVAC Biotech Ltd. announced the Company’s subsidiary SINOVAC Biotech Co., Ltd (“SINOVAC Beijing”) settled the litigation with Mr. Aihua Pan concerning its business license and seals.
-
Preliminary Results Show SINOVAC’s COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population
11/9/2021
SINOVAC Biotech Ltd. announced new preliminary data on its inactivated COVID-19 vaccine CoronaVac®.
-
COVID News: Vaccinated Death Toll Much Lower, Moderna Gets Thumbs Down from France and More
11/9/2021
New studies come out regularly supporting the efficacy and safety of the COVID-19 vaccines. Here’s a look as well as other COVID-19 news. -
Everest will pay Providence $50 million in cash upfront for access to its COVID-19 vaccine and other mRNA vaccine candidates targeting specific variants in earlier stages of development.
-
New Research on SINOVAC’s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant
9/9/2021
SINOVAC Biotech Ltd., a leading provider of biopharmaceutical products in China, announced a paper, titled “A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2,” is available on medRxiv.
-
SINOVAC Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Children and Adolescents
9/8/2021
SINOVAC Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that CoronaVac®, an innovative, inactivated coronavirus vaccine developed by SINOVAC Life Sciences Co., Ltd., a subsidiary of the Company, received approval from the Public Health Institute of Chile for emergency use for children and adolescents aged between 6 and 17.
-
SINOVAC Announces Positive Data on Booster Shots of CoronaVac®, Induces Strong Immune Response in Adult and Elderly Populations
8/10/2021
CoronaVac® generates good immune memory after second dose. Third dose of vaccine significantly increased neutralizing antibody levels in adults and elderly population.
-
Moderna continues to assess its COVID-19 vaccine in juveniles, the company is expanding the study to include protocols to detect the potential of rare side effects, including heart inflammation.
-
SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine (sIPV) to Support Global Polio Endgame Strategy
7/19/2021
SINOVAC Biotech Ltd., a leading provider of biopharmaceutical products in China, announced it received a drug registration approval from the National Medical Product Administration of China for its Sabin strain based inactivated polio vaccine on July 12, 2021.
-
SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX
7/12/2021
SINOVAC Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that it had signed an advance purchase agreement with Gavi, the Vaccine Alliance, which is on behalf of COVAX Facility, to provide up to 380 million doses of inactivated COVID-19 vaccine, CoronaVac®for distribution through the COVAX Facility.
-
Sinovac’s CoronaVac was the first COVID-19 vaccine approved in China for emergency use back in June 2020.